[go: up one dir, main page]

CR8778A - Revestimientos de azucar y metodos para estos - Google Patents

Revestimientos de azucar y metodos para estos

Info

Publication number
CR8778A
CR8778A CR8778A CR8778A CR8778A CR 8778 A CR8778 A CR 8778A CR 8778 A CR8778 A CR 8778A CR 8778 A CR8778 A CR 8778A CR 8778 A CR8778 A CR 8778A
Authority
CR
Costa Rica
Prior art keywords
methods
coatings
sugar coatings
solid dose
dose forms
Prior art date
Application number
CR8778A
Other languages
English (en)
Inventor
John C Clark
John J Michelucci
Deborah M Sherman
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of CR8778A publication Critical patent/CR8778A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2072Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/28Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806Coating materials
    • A61K9/282Organic compounds, e.g. fats
    • A61K9/2826Sugars or sugar alcohols, e.g. sucrose; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/28Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806Coating materials
    • A61K9/2833Organic macromolecular compounds
    • A61K9/286Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/28Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2886Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/24Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30Oestrogens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/24Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/34Gestagens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2013Organic compounds, e.g. phospholipids, fats
    • A61K9/2018Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Medicinal Preparation (AREA)
  • Paints Or Removers (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Se proveen las composiciones particularmente utiles como revestimientos para formas de dosis en solidos de agentes terapeuticos, que se encuentran como formas de dosis en solidos que comprenden dichos revestimientos, procedimientos para la preparacion de dichas formas de dosis en solidos, y los productos de estos procedimientos.
CR8778A 2004-06-07 2006-12-01 Revestimientos de azucar y metodos para estos CR8778A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US57766804P 2004-06-07 2004-06-07

Publications (1)

Publication Number Publication Date
CR8778A true CR8778A (es) 2007-10-01

Family

ID=35351681

Family Applications (1)

Application Number Title Priority Date Filing Date
CR8778A CR8778A (es) 2004-06-07 2006-12-01 Revestimientos de azucar y metodos para estos

Country Status (23)

Country Link
US (2) US20050271724A1 (es)
EP (1) EP1753407B1 (es)
JP (1) JP5000509B2 (es)
CN (1) CN101267809A (es)
AR (1) AR049142A1 (es)
AU (1) AU2005251793B2 (es)
BR (1) BRPI0511663A (es)
CA (1) CA2566771A1 (es)
CR (1) CR8778A (es)
EC (1) ECSP067049A (es)
ES (1) ES2623363T3 (es)
GT (1) GT200500141A (es)
IL (1) IL179537A0 (es)
MX (1) MXPA06014229A (es)
NO (1) NO20070091L (es)
NZ (1) NZ551676A (es)
PA (1) PA8636001A1 (es)
PE (1) PE20060245A1 (es)
RU (1) RU2428178C2 (es)
SV (1) SV2006002136A (es)
TW (1) TW200602089A (es)
UA (1) UA86413C2 (es)
WO (1) WO2005120466A2 (es)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0602397C1 (pt) * 2006-04-20 2009-11-24 Unicamp composições farmacêuticas para o tratamento das doenças gordurosas do fìgado, obesidade e demais doenças associadas à sìndrome metabólica e métodos de tratamento utilizando-se as referidas composições
JP5198001B2 (ja) * 2006-06-23 2013-05-15 武田薬品工業株式会社 安定化された固形製剤
US20100047349A1 (en) * 2006-06-23 2010-02-25 Takeda Pharmaceutical Company Limited Stabilized solid preparation
CN101495101B (zh) * 2006-07-25 2012-02-29 兴和株式会社 糖衣制剂及其制造方法
CA2670544A1 (en) * 2006-11-29 2008-06-05 Wyeth Estrogen/ serm and estrogen/ progestin bi-layer tablets
PE20081632A1 (es) * 2007-01-12 2008-12-10 Wyeth Corp Composiciones de tableta en tableta
US20090012146A1 (en) * 2007-07-02 2009-01-08 Giridhar Reddy Buggana Solubility-enhanced pharmaceutical compositions comprising zafirlukast
US20090232897A1 (en) * 2008-03-14 2009-09-17 Bijayananda Sahoo Pharmaceutical compositions comprising conjugated estrogens
US20090274757A1 (en) * 2008-05-01 2009-11-05 Wyeth Pharmaceutical polish formulations
US20090324714A1 (en) * 2008-06-27 2009-12-31 Wyeth Dual adhesive technology
CN101744725B (zh) * 2008-12-09 2013-04-17 北京华素制药股份有限公司 缓释微丸包衣生产工艺参数的优化方法
EP2375903A4 (en) * 2008-12-15 2012-09-19 Somnus Therapeutics Inc METHOD FOR TREATING SILENTNESS
RU2410100C2 (ru) * 2009-03-30 2011-01-27 Александр Владимирович Диковский Фармацевтическая композиция ингибитора протонной помпы и пребиотика для лечения язвенных поражений желудка и 12-перстной кишки
US20110052687A1 (en) * 2009-08-26 2011-03-03 Glenmark Generics Ltd Extended release pharmaceutical composition of paliperidone
JP2013504562A (ja) * 2009-09-17 2013-02-07 カディラ・ヘルスケア・リミテッド アルコールで誘発される用量ダンピングを低減するための医薬組成物
US8663671B2 (en) * 2009-11-05 2014-03-04 Philip Morris Usa Inc. Methods and compositions for producing hydrogel capsules coated for low permeability and physical integrity
ES2709766T3 (es) * 2010-03-09 2019-04-17 Alkermes Pharma Ireland Ltd Composiciones farmacéuticas entéricas resistentes al alcohol
EP2568973A2 (en) 2010-05-11 2013-03-20 Sensient Colors LLC Film coating composition and methods of making and using the same
RS54447B1 (sr) * 2011-01-20 2016-06-30 Bionevia Pharmaceuticals Inc. Modifikovano oslobađajuće kompozicije epalrestata ili njegovih derivata i postupci njihove upotrebe
US8846089B2 (en) * 2011-06-03 2014-09-30 Wakunaga Pharmaceutical Co., Ltd. Sugar-coated preparation and production method for the same
CN103385876B (zh) * 2012-05-08 2016-01-13 四川滇虹医药开发有限公司 一种夫罗曲坦的药物组合物及其制备方法
FR2996128B1 (fr) * 2012-09-28 2015-01-02 Inneov Lab Utilisation d'une association de taurine ou un de ses derives, et d'extrait de raisins pour ameliorer la qualite des ongles.
CN103977427A (zh) * 2014-05-08 2014-08-13 王�琦 一种糖衣产气粉配方及其制备方法
US20170196816A1 (en) * 2014-06-02 2017-07-13 Nipro Corporation Laser-printable tablet, and method for manufacturing the same
WO2016108250A1 (en) 2015-01-01 2016-07-07 Ideal Cures Pvt. Ltd. Novel film coating composition
US20180000742A1 (en) * 2015-01-29 2018-01-04 Novo Nordisk A/S Pharmaceutical Composition for Oral Insulin Administration Comprising a Tablet Core and a Polyvinyl Alcohol Coating
RU2588840C1 (ru) * 2015-03-26 2016-07-10 Общество с ограниченной ответственностью ООО "ВАЛЕНТА-ИНТЕЛЛЕКТ" Таблетки кветиапина с пролонгированным высвобождением и способ их получения
CA2937365C (en) 2016-03-29 2018-09-18 F. Hoffmann-La Roche Ag Granulate formulation of 5-methyl-1-phenyl-2-(1h)-pyridone and method of making the same
CA3031671C (en) * 2016-08-04 2024-10-29 Bpsi Holdings, Llc EASY-TO-SWALLOW COATINGS AND SUBSTRATES COATED WITH THESE
FR3069545B1 (fr) * 2017-07-27 2020-10-16 Soc Dexploitation De Produits Pour Les Industries Chimiques Seppic Composition d'enrobage exempte de dioxyde de titane
FR3089756B1 (fr) * 2018-12-17 2021-02-19 Roquette Freres Formes solides dragéifiées présentant une stabilité améliorée
MX2019008440A (es) * 2019-07-15 2021-01-18 Dva Farma Mexicana S A De C V Composiciones de recubrimientos en pelicula para tabletas con brillantez incrementada, procedimiento de preparacion y aplicacion.

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2565115A (en) 1948-10-28 1951-08-21 Squibb & Sons Inc Method of obtaining a conjugated estrogen preparation
US2720483A (en) 1951-02-21 1955-10-11 Olin Mathieson Method of obtaining a conjugatedestrogen preparation
US3487152A (en) * 1967-02-07 1969-12-30 Hoffmann La Roche Tablets containing 7 - chloro - 2 - methylamino - 5 - phenyl - 3h - 1,4 - benzodiazepine-4-oxide and conjugated estrogenic substances
JPS625910A (ja) * 1985-07-02 1987-01-12 Shin Etsu Chem Co Ltd 薄層糖衣錠の製造方法
US5210081A (en) * 1992-02-26 1993-05-11 American Home Products Corporation Alkali metal 8,9-dehydroestrone sulfate esters
WO1995006462A1 (en) * 1993-08-30 1995-03-09 Warner-Lambert Company Tablet coating based on a melt-spun mixture of a saccharide and apolymer
US5759577A (en) * 1995-01-17 1998-06-02 American Home Products Corporation Controlled release of steroids from sugar coatings
US5547948A (en) * 1995-01-17 1996-08-20 American Home Products Corporation Controlled release of steroids from sugar coatings
WO1997004752A1 (en) * 1995-07-26 1997-02-13 Duramed Pharmaceuticals, Inc. Pharmaceutical compositions of conjugated estrogens and methods for their use
US6248391B1 (en) * 1997-07-16 2001-06-19 Bpsi Holdings, Inc. Bright white film coatings and film coating compositions therefor
HK1049624A1 (zh) * 1999-03-29 2003-05-23 Wyeth 包衣系统
US6630166B1 (en) * 2001-02-12 2003-10-07 Watson Pharmaceuticals, Inc. Compositions for conjugated estrogens and associated methods
US20030070584A1 (en) * 2001-05-15 2003-04-17 Cynthia Gulian Dip coating compositions containing cellulose ethers
WO2003075918A1 (fr) * 2002-03-14 2003-09-18 Daiichi Suntory Pharma Co.,Ltd. Comprime contenant du chlorhydrate de pilsicainide (voie humide)

Also Published As

Publication number Publication date
BRPI0511663A (pt) 2008-01-02
AU2005251793A1 (en) 2005-12-22
ECSP067049A (es) 2007-02-28
WO2005120466A3 (en) 2007-04-19
EP1753407A2 (en) 2007-02-21
UA86413C2 (ru) 2009-04-27
RU2428178C2 (ru) 2011-09-10
RU2006140093A (ru) 2008-07-20
GT200500141A (es) 2006-01-10
US20050271724A1 (en) 2005-12-08
CA2566771A1 (en) 2005-12-22
IL179537A0 (en) 2007-05-15
NO20070091L (no) 2007-01-05
WO2005120466A2 (en) 2005-12-22
AR049142A1 (es) 2006-06-28
TW200602089A (en) 2006-01-16
ES2623363T3 (es) 2017-07-11
EP1753407B1 (en) 2017-03-08
SV2006002136A (es) 2006-02-15
JP5000509B2 (ja) 2012-08-15
MXPA06014229A (es) 2007-05-04
AU2005251793B2 (en) 2010-07-15
JP2008501803A (ja) 2008-01-24
PA8636001A1 (es) 2006-05-16
US20110136772A1 (en) 2011-06-09
NZ551676A (en) 2010-11-26
CN101267809A (zh) 2008-09-17
PE20060245A1 (es) 2006-05-03

Similar Documents

Publication Publication Date Title
CR8778A (es) Revestimientos de azucar y metodos para estos
ECSP10010548A (es) Composiciones y metodos de preparacion y uso de las mismas
ECSP088329A (es) Nuevos diazaespiroalcanos y su uso para el tratamiento de enfermedades mediadas por ccr8
CL2008002793A1 (es) Compuestos derivados de amidas sustituidas, inhibidores de la actividad de btk; composicion farmaceutica que los comprende; utiles en el tratamiento del cancer, trastornos oseos, enfermedades autoinmunes, entre otras
UY31747A (es) Nuevas formulaciones, comprimidos que comprenden tales formulaciones, su uso y procedimiento para su preparacion
ECSP109934A (es) Compuesto - 946
SV2010003559A (es) Algunos derivados de 2-pirazinona y su uso como inhibidores de elastasa de los neutrofilos
ECSP088440A (es) Imidazopirazinas como inhibidores de proteinquinasa
ECSP077235A (es) Benzamidas sustituidas por trifluoro-metilo como inhibidores de quinasa
PA8720801A1 (es) Nuevas combinaciones terapeuticas para el tratamiento de la depresion
EA201170036A1 (ru) Соединения боронатного эфира и его фармацевтические составы
CL2009000349A1 (es) Compuestos derivados de 4,5-dihidro-oxazol-2-ilamina; procedimiento de preparacion; composicion farmaceutica; y su uso para el tratamiento de la enfermedad de alzheimer.
CR20200334A (es) Compuestos, composiciones y métodos para tratar enfermedades que involucren tejidos con enfermedades ácidas o hipóxicas
CL2012002497A1 (es) Compuestos derivados de imidazopirimidina,sustituidos, inhibidores de la pde10a; procedimiento de preparacion; composicion farmaceutica; y su uso para el tratamiento o prevencion de trastornos psicoticos, esquizofrenia, enfermedad de parkinson, esclerosis multiple, entre otras.
CL2011000973A1 (es) Compuestos derivados de pirazolo [1,5-a]pirimidina3-cabroxamida; composicion farmaceutica que los comprende, y uso para tratar o disminuir la gravedad de una enfermedad o condicion que responde a la inhibicion de la actividad de una jak quinasa.
ECSP066794A (es) Nuevos compuestos como inhibidores de serina proteasa ns3 del virus de la hepatitis c
UY29796A1 (es) Nuevos compuestos para el tratamiento de trastornos neurológicos, psiquiátricos o del dolor
HN2008000311A (es) Formas cristalinas de 4-metil-n-[3-(4-metil-imidazol-1-il)-5-trifluorometil-fenil]-3-(4-piridin-3-il-pirimidin-2-ilamino)-benzamida
UY29087A1 (es) Derivados de adamantilo, composiciones farmaceuticas que los contienen, procesos para su preparacion y uso terapeutico
MX2022005563A (es) Ligandos de la pseudoquinasa tyk2.
UY31860A (es) Piridinas de tiazolo como inhibidoras de la adn girasa
ECSP088366A (es) 1,2-diarilimidazoles para uso como moduladores de cb1
BRPI0606132A2 (pt) formas cristalinas de docetaxel e processos para seu preparo
ECSP088250A (es) Derivados de pirazol como agentes terapéuticos
CL2007003251A1 (es) Compuestos derivados de 1h-pirazoles sustituidos, inhibidores de reacciones catalizadas por una quinasa; su procedimiento de preparacion; composicion farmaceutica; compuestos intermediarios; uso de los compuestos principales, utiles en el tratamiento del cancer.

Legal Events

Date Code Title Description
FA Abandonment or withdrawal (granting procedure)